Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Amortization - Intangibles data on file, last reported at $29.5 million in Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $29.5 million, up 66.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.4 million (up 24.44% YoY), and the FY2025 annual result was $76.7 million, up 7.9% from the prior year.
• Amortization - Intangibles rose to $29.5 million in Q1 2026 per HALO's latest filing, from $23.4 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $29.5 million in Q1 2026 and troughed at $4.6 million in Q4 2022.
• A 5-year average of $18.4 million and a median of $17.8 million in 2023 frame the typical range for Amortization - Intangibles.
• On a YoY basis, Amortization - Intangibles climbed as much as 290.2% in 2023 and fell as far as 25.2% in 2023.
• A 5-year view of Amortization - Intangibles shows it stood at $4.6 million in 2022, then surged by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then soared by 31.61% to $23.4 million in 2025, then climbed by 26.25% to $29.5 million in 2026.
• Business Quant data shows HALO's Amortization - Intangibles at $29.5 million in Q1 2026, $23.4 million in Q4 2025, and $17.8 million in Q3 2025.